Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis.

Conclusions: The SIRI ≥ 1.9 independently prognosticated significantly worse OS and PFS results and plated the stage IIIB/C patients into three fundamentally distinct prognostic groups. PMID: 33552158 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/33552158?dopt=Abstract

Source: Journal of Oncology - February 9, 2021 Category: Cancer & Oncology Tags: J Oncol Source Type: research

More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study